Atrium Therapeutics spends $270 million to launch RNA therapy to treat rare heart disease

Atrium was spun off from Avidity Biosciences, which Novartis acquired in a $12 billion deal. Atrium's pipeline is led by two RNA therapies that treat rare genetic heart diseases for which there are no FDA-approved drugs.

The post Atrium Therapeutics launches $270M RNA therapy to tackle rare heart disease appeared first on MedCity News.